21:06 , Sep 21, 2017 |  BC Innovations  |  Translation in Brief

Driving CARs into neuroblastoma

In separate studies published in the same July issue of the Proceedings of the National Academies of Sciences, NCI and Karolinska Institute teams each discovered a new target for high-risk forms of neuroblastoma. The former...
07:00 , Sep 19, 2016 |  BioCentury  |  Emerging Company Profile

Solid CARs

Long-standing doubts about whether CAR T cells would be effective against solid tumors were exacerbated last year after Novartis AG and the University of Pennsylvania reported that their CART-meso showed no complete or partial responses...
07:00 , Jul 13, 2015 |  BioCentury  |  Strategy

Celgene's Juno juggernaut

In just a few months, Celgene Corp.'s long game in hematologic malignancies has become clear: a focus on immuno-oncology. A billion dollar decade-long collaboration with Juno Therapeutics Inc. is the big biotech's most recent deal...
07:00 , Apr 27, 2015 |  BioCentury  |  Finance

CAR talk

While investors in Kite Pharma Inc. (NASDAQ:KITE) and Juno Therapeutics Inc. (NASDAQ:JUNO) will soon be combing through American Society of Clinical Oncology abstracts, they shouldn't hold their breath for efficacy data for the CAR T...
07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer L1 cell adhesion molecule (L1CAM; CD171) Studies in patient samples and mice suggest inhibiting CD171...
07:00 , Jul 21, 2008 |  BC Week In Review  |  Company News

Celltrion, Medigene, German Cancer Research Center deal

MediGene exercised an option to acquire an exclusive, worldwide license from the center to develop and commercialize a mAb against L1 cell adhesion molecule ( L1CAM, CD171) to treat cancer under a 2006...